Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytek Biosciences (CTKB) Operating Expenses (2020 - 2025)

Historic Operating Expenses for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to $36.7 million.

  • Cytek Biosciences' Operating Expenses rose 1049.53% to $36.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.0 million, marking a year-over-year increase of 214.99%. This contributed to the annual value of $131.6 million for FY2024, which is 411.01% down from last year.
  • Latest data reveals that Cytek Biosciences reported Operating Expenses of $36.7 million as of Q3 2025, which was up 1049.53% from $34.5 million recorded in Q2 2025.
  • Cytek Biosciences' Operating Expenses' 5-year high stood at $37.3 million during Q2 2023, with a 5-year trough of $13.4 million in Q1 2021.
  • In the last 5 years, Cytek Biosciences' Operating Expenses had a median value of $33.2 million in 2023 and averaged $28.8 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first soared by 10640.09% in 2021, then tumbled by 891.95% in 2024.
  • Over the past 5 years, Cytek Biosciences' Operating Expenses (Quarter) stood at $22.3 million in 2021, then surged by 31.23% to $29.3 million in 2022, then grew by 13.3% to $33.2 million in 2023, then decreased by 7.59% to $30.7 million in 2024, then grew by 19.82% to $36.7 million in 2025.
  • Its Operating Expenses was $36.7 million in Q3 2025, compared to $34.5 million in Q2 2025 and $35.1 million in Q1 2025.